Elective pelvic nodal irradiation (EPNI) remains a controversial area in prostate cancer management. Two articles published in the International Journal of Radiation, Oncology, Biology and Physics present additional data regarding the benefits of EPNI for patients with high-risk prostate cancer, suggesting that EPNI confers no benefit in overall survival or biochemical-progression-free survival.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Amini, A. et al. Survival outcomes of whole-pelvic versus prostate-only radiotherapy for high risk prostate cancer patients using the National Cancer Data Base. Int. J. Radiat. Oncol. Biol. Phys. http://dx.doi.org/10.1016/j.ijrobp.2015.09.006.
Blanchard, P. et al. Outcome according to elective pelvic radiotherapy in patients with high-risk localized prostate cancer: a secondary analysis of the GETUG 12 Phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. http://dx.doi.org/10.1016/j.ijrobp.2015.09.020.
Morikawa, L. K. & Roach, M. 3rd. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int. J. Radiat. Oncol. Biol. Phys. 80, 6–16 (2011).
Lawton, C. A. et al. An update of the Phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int. J. Radiat. Oncol. Biol. Phys. 69, 646–655 (2007).
NRG Oncology. Androgen deprivation therapy and radiotherapy in treating patients with prostate cancer. Cancer.gov [online].
US National Library of Science. A Phase III Trial of cabazetaxel and pelvic radiotherapy for localized prostate cancer with high risk features for relapse (PEACE2). ClinicalTrials.gov [online].
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Crook, J. Elective pelvic nodal radiotherapy: is the jury still out?. Nat Rev Urol 13, 10–11 (2016). https://doi.org/10.1038/nrurol.2015.283
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.283